



Via Hand Delivery 04 May 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE MAY 08 2001

TECH CENTER 1600/2900

In re application of: Gentz et al.

Application Serial No.: 09/518,931

Filed: March 3, 2000

For: Tumor Necrosis Factor

Receptors 6alpha & 6beta

Art Unit: 1632

Examiner: O'Hara, E.

Attorney Docket No.: PF454P1

16/B
D.9J
5/14/01

RESPONSE UNDER 37 C.F.R. §1.111 TO PAPER NO. 14

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed February 27, 2001, Applicants request that the following amendments and remarks be entered into the above-identified application. Applicants submit herewith: (a) Version with markings to show changes made (3 pages); (b) a Request for Correction of Filing Receipt (2 pages); (c) an Information Disclosure Statement Pursuant to 37 C.F.R. § 1.56 (with a revised Form PTO/SB/08 and copies of references BW-CC); and (d) a Fee Transmittal Sheet.

In the Specification:

Please replace the first paragraph of the application beginning on line 3 of page 1, with the following amended paragraph:

B1
This application is a continuation-in-part of application serial No. 09/006,352, filed 13 January, 1998, priority to which is hereby claimed under 35 U.S.C. §120. Application Serial No. 09/006,352, in turn, claims the benefit of priority under 35 U.S.C. §119(e) based on U.S. Provisional Application Serial No. 60/035,496, filed January 14, 1997. This application also claims the benefit of priority under 35 U.S.C. §119(e) based on the following U.S. Provisional Applications: Serial No. 60/121,774, filed 04 March 1999, Serial No.